NO305125B1 - Farmas°ytiske forbindelser - Google Patents

Farmas°ytiske forbindelser

Info

Publication number
NO305125B1
NO305125B1 NO931917A NO931917A NO305125B1 NO 305125 B1 NO305125 B1 NO 305125B1 NO 931917 A NO931917 A NO 931917A NO 931917 A NO931917 A NO 931917A NO 305125 B1 NO305125 B1 NO 305125B1
Authority
NO
Norway
Prior art keywords
alkyl
pharmaceutical compounds
optionally substituted
cycloalkyl
alkyl groups
Prior art date
Application number
NO931917A
Other languages
English (en)
Norwegian (no)
Other versions
NO931917D0 (no
NO931917L (no
Inventor
John Fairhurst
Terrence Michael Hotten
David Edward Tupper
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of NO931917D0 publication Critical patent/NO931917D0/no
Publication of NO931917L publication Critical patent/NO931917L/no
Publication of NO305125B1 publication Critical patent/NO305125B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO931917A 1992-05-29 1993-05-26 Farmas°ytiske forbindelser NO305125B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (3)

Publication Number Publication Date
NO931917D0 NO931917D0 (no) 1993-05-26
NO931917L NO931917L (no) 1993-11-30
NO305125B1 true NO305125B1 (no) 1999-04-06

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
NO931917A NO305125B1 (no) 1992-05-29 1993-05-26 Farmas°ytiske forbindelser

Country Status (21)

Country Link
EP (1) EP0582368B1 (de)
JP (1) JP3219541B2 (de)
CN (1) CN1043994C (de)
AT (1) ATE198891T1 (de)
AU (1) AU668159B2 (de)
CA (1) CA2097016A1 (de)
CZ (1) CZ282783B6 (de)
DE (1) DE69329887T2 (de)
DK (1) DK0582368T3 (de)
ES (1) ES2153373T3 (de)
FI (1) FI101538B1 (de)
GR (1) GR3035587T3 (de)
HU (1) HU218278B (de)
IL (1) IL105827A (de)
MX (1) MX9303124A (de)
MY (1) MY109943A (de)
NO (1) NO305125B1 (de)
NZ (1) NZ247703A (de)
PT (1) PT582368E (de)
RU (1) RU2125574C1 (de)
TW (1) TW268005B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
AU721338B2 (en) * 1996-03-25 2000-06-29 Eli Lilly And Company Method for treating pain
BR9708254A (pt) * 1996-03-25 1999-08-03 Lilly Co Eli Método para o tratamento da dor
CA2250186A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating migraine pain
RS49597B (sr) 1996-09-23 2007-06-04 Eli Lilly And Company, Olanzapin dihidrat d
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
JP2001501207A (ja) * 1996-09-24 2001-01-30 イーライ・リリー・アンド・カンパニー コーティングされた粒子製剤
AU2013305936B2 (en) 2012-08-21 2017-08-03 Saladax Biomedical Inc. Haptens of risperidone and paliperidone
PL2888286T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PL2888258T3 (pl) 2012-08-21 2019-10-31 Janssen Pharmaceutica Nv Hapteny paliperydonu
PL3462173T3 (pl) 2012-08-21 2021-08-16 Janssen Pharmaceutica Nv Przeciwciała przeciwko rysperydonowi i ich zastosowanie
CA2882557C (en) 2012-08-21 2020-10-27 Ortho-Clinical Diagnostics, Inc. Haptens of quetiapine for use in immunoassays
EP2888277A4 (de) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc Antikörper gegen paliperidon und verwendung davon
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
ES2822914T3 (es) 2012-08-21 2021-05-05 Janssen Pharmaceutica Nv Haptenos de aripiprazol y su uso en inmunoensayos
ES2807902T3 (es) 2012-08-21 2021-02-24 Janssen Pharmaceutica Nv Anticuerpos para olanzapina y uso de los mismos
AU2013305970B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to aripiprazole haptens and use thereof
EP2888284B1 (de) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Antikörper gegen risperidon-haptene und verwendungen davon
EP3581195A1 (de) 2012-08-21 2019-12-18 Janssen Pharmaceutica NV Antikörper gegen olanzapinhaptene und verwendung davon
PT2888373T (pt) 2012-08-21 2018-06-12 Janssen Pharmaceutica Nv Anticorpos contra aripiprazole e seu uso
PL2888592T3 (pl) 2012-08-21 2018-03-30 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
PL2888269T3 (pl) * 2012-08-21 2019-06-28 Janssen Pharmaceutica Nv Hapteny olanzapiny
JP6994461B2 (ja) 2015-12-17 2022-02-04 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンに対する抗体及びその使用
WO2017106501A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
FI762646A (de) * 1975-09-24 1977-03-25 Sandoz Ag
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
IL105827A (en) 1997-02-18
DK0582368T3 (da) 2001-02-05
HUT66180A (en) 1994-09-28
EP0582368A1 (de) 1994-02-09
AU3980793A (en) 1993-12-02
CN1043994C (zh) 1999-07-07
NO931917D0 (no) 1993-05-26
FI101538B (fi) 1998-07-15
IL105827A0 (en) 1993-09-22
DE69329887T2 (de) 2001-05-23
CN1085903A (zh) 1994-04-27
CA2097016A1 (en) 1993-11-30
ATE198891T1 (de) 2001-02-15
HU9301579D0 (en) 1993-09-28
MY109943A (en) 1997-10-31
RU2125574C1 (ru) 1999-01-27
ES2153373T3 (es) 2001-03-01
CZ282783B6 (cs) 1997-10-15
NZ247703A (en) 1995-07-26
GR3035587T3 (en) 2001-06-29
DE69329887D1 (de) 2001-03-01
FI932445A (fi) 1993-11-30
EP0582368B1 (de) 2001-01-24
JP3219541B2 (ja) 2001-10-15
MX9303124A (es) 1993-11-01
FI932445A0 (fi) 1993-05-28
AU668159B2 (en) 1996-04-26
HU218278B (en) 2000-07-28
NO931917L (no) 1993-11-30
CZ102493A3 (en) 1993-12-15
PT582368E (pt) 2001-05-31
TW268005B (de) 1996-01-11
JPH0687862A (ja) 1994-03-29
FI101538B1 (fi) 1998-07-15

Similar Documents

Publication Publication Date Title
NO305125B1 (no) Farmas°ytiske forbindelser
KR930703355A (ko) 항생물질 ge2270 인자의 아미드
KR870700620A (ko) 신규 약리학적 화합물
CZ284872B6 (cs) Cyklické močoviny a jejich analogy a farmaceutické přípravky na jejich bázi
DK0674513T3 (da) Retroviral protease-inhiberende forbindelser
PH25859A (en) Composition for treatment of ischemic disorder
ES2143526T3 (es) Derivados de amida que tienen actividad antihipercolesterolemica, su preparacion y sus usos terapeuticos.
DE69231661T2 (de) Antifungizide trisubstituierte tetrahydrofurane
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
SE9100920D0 (sv) New active compounds
BR9503536A (pt) Composto processo para sua preparação seu uso e composição farmacêutica
ATE117989T1 (de) Prostaglandinanaloge enthaltende lipidemulsion.
FI891279A (fi) Antivirala tetrahydroimidazol /1,4/ benzodiazepin-2-oner.
FI103046B1 (fi) Menetelmä lääkeaineina käyttökelpoisten pyrrolidinyylitiokarbapeneemijohdannaisten valmistamiseksi
DE3371627D1 (en) Acetylsalicylic acid thioesters, a process for their preparation and pharmaceutical compositions containing them
TW275629B (de)
DE3867494D1 (de) Fluor enthaltende vitamin-d2-derivate.
ES2037825T3 (es) Uso farmaceutico de tioeteres aromaticos.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN NOVEMBER 2002